BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...